TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction
Brief Summary: The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).


Options:
A: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
B: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: MEDI528 50 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 50 mg | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: BIOLOGICAL; Name: MEDI528 50 mg; Assigned to Arm(s): MEDI528 50 mg | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma
Brief Summary: Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting. Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.


Options:
A: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: hu14.18-IL2 | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: hu14.18-IL2 | Intervention Type: DRUG; Name: hu14.18-IL2; Assigned to Arm(s): A | Intervention Type: DRUG; Name: hu14.18-IL2; Assigned to Arm(s): B
C: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combining Medications to Enhance Depression Outcomes
Brief Summary: This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.


Options:
A: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention
B: Arm Label: Deprexis; Type: EXPERIMENTAL; Interventions: Behavioral: Deprexis | Arm Label: Wait-list; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Deprexis, Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Deprexis; Assigned to Arm(s): Deprexis, Wait-list | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list
C: Arm Label: SSRI + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: SSRI + placebo | Arm Label: Escitalopram + Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + Bupropion SR | Arm Label: Venlafaxine XR + Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine XR + Mirtazapine | Intervention Type: DRUG; Name: SSRI + placebo; Assigned to Arm(s): SSRI + placebo | Intervention Type: DRUG; Name: Escitalopram + Bupropion SR; Assigned to Arm(s): Escitalopram + Bupropion SR | Intervention Type: DRUG; Name: Venlafaxine XR + Mirtazapine; Assigned to Arm(s): Venlafaxine XR + Mirtazapine
D: Arm Label: Nurse case management and self-management support; Type: EXPERIMENTAL; Interventions: Other: Nurse case management and self-management support | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nurse case management and self-management support; Assigned to Arm(s): Nurse case management and self-management support

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combining Medications to Enhance Depression Outcomes
Brief Summary: This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.


Options:
A: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
B: Arm Label: Nurse case management and self-management support; Type: EXPERIMENTAL; Interventions: Other: Nurse case management and self-management support | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nurse case management and self-management support; Assigned to Arm(s): Nurse case management and self-management support
C: Arm Label: Index group; Type: ACTIVE_COMPARATOR; Interventions: Other: Index group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Index group; Assigned to Arm(s): Index group
D: Arm Label: SSRI + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: SSRI + placebo | Arm Label: Escitalopram + Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + Bupropion SR | Arm Label: Venlafaxine XR + Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine XR + Mirtazapine | Intervention Type: DRUG; Name: SSRI + placebo; Assigned to Arm(s): SSRI + placebo | Intervention Type: DRUG; Name: Escitalopram + Bupropion SR; Assigned to Arm(s): Escitalopram + Bupropion SR | Intervention Type: DRUG; Name: Venlafaxine XR + Mirtazapine; Assigned to Arm(s): Venlafaxine XR + Mirtazapine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Exercise on Individuals With Parkinson's Disease
Brief Summary: The goal of this trial is to compare the effect of two different exercise programs on neuro-physiological, motor, functional, and quality-of-life issues in individuals with Parkinson's disease to determine which program is most beneficial.


Options:
A: Arm Label: virtual reality balance training; Type: EXPERIMENTAL; Interventions: Behavioral: balance training | Arm Label: conventional balance training; Type: EXPERIMENTAL; Interventions: Behavioral: balance training | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: balance training; Assigned to Arm(s): conventional balance training, virtual reality balance training
B: Arm Label: Progressive resistance training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Progressive resistance training | Arm Label: Modified Fitness Counts; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Modified Fitness Counts | Intervention Type: BEHAVIORAL; Name: Progressive resistance training; Assigned to Arm(s): Progressive resistance training | Intervention Type: BEHAVIORAL; Name: Modified Fitness Counts; Assigned to Arm(s): Modified Fitness Counts
C: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary Care | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Multidisciplinary Care; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women
Brief Summary: This is a multi-center study to evaluate the effects of SCE-B on nocturnal vasomotor symptoms. Study duration will be approximately 16 weeks; this includes a 4-week screening period and approximately 5 scheduled clinic visits. Participants will receive one of two strengths of SCE-B tablets plus matching placebo or placebo only, and will have a physical and gynecological exams that may include transvaginal ultrasound, endometrial biopsy and a pap smear. Participants will be asked to wear a monitoring device for a portion of the study and be asked to complete a daily dairy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SCE-B, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: SCE-B, Drug: Placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SCE-B; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: estradiol, 10 mcg; Assigned to Arm(s): N/A
D: Arm Label: faslodex+placebo; Type: EXPERIMENTAL; Interventions: Drug: faslodex 500mg, Drug: arimidex dummy | Arm Label: arimidex +placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: arimidex 1mg, Drug: faslodex dummy | Intervention Type: DRUG; Name: faslodex 500mg; Assigned to Arm(s): faslodex+placebo | Intervention Type: DRUG; Name: arimidex 1mg; Assigned to Arm(s): arimidex +placebo | Intervention Type: DRUG; Name: faslodex dummy; Assigned to Arm(s): arimidex +placebo | Intervention Type: DRUG; Name: arimidex dummy; Assigned to Arm(s): faslodex+placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study
Brief Summary: The purpose of this study is to determine the effect of calcium 1000 mg/d and vitamin-D3 800 IU/d divided in two daily doses on the incidence of falls and fractures, bone mineral density and bone metabolism in postmenopausal women 65-71 years of age.


Options:
A: Arm Label: Ia; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate and cholecalciferol | Arm Label: Ib; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate and cholecalciferol | Arm Label: IIa; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IIb; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium carbonate and cholecalciferol; Assigned to Arm(s): Ia, Ib
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
C: Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cure | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study 1. Phase I Study of Feasibility and Safety.
Brief Summary: This is a pilot study to test feasibility of collection, preparation and infusion of a baby's own (autologous)umbilical cord blood in the first 14 days after birth if the baby is born with signs of brain injury.


Options:
A: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: erythropoietin | Intervention Type: DRUG; Name: erythropoietin; Assigned to Arm(s): A
C: Arm Label: EPO HIE Group; Type: EXPERIMENTAL; Interventions: Drug: Human recombinant erythropoietin, Procedure: EEG and Brain MRI, Biological: Nitric oxide measurement in the blood | Arm Label: Control HIE; Type: NO_INTERVENTION; Interventions: Procedure: EEG and Brain MRI, Biological: Nitric oxide measurement in the blood | Arm Label: Healthy Controls; Type: OTHER; Interventions: Biological: Nitric oxide measurement in the blood | Intervention Type: DRUG; Name: Human recombinant erythropoietin; Assigned to Arm(s): EPO HIE Group | Intervention Type: PROCEDURE; Name: EEG and Brain MRI; Assigned to Arm(s): Control HIE, EPO HIE Group | Intervention Type: BIOLOGICAL; Name: Nitric oxide measurement in the blood; Assigned to Arm(s): Control HIE, EPO HIE Group, Healthy Controls
D: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study 1. Phase I Study of Feasibility and Safety.
Brief Summary: This is a pilot study to test feasibility of collection, preparation and infusion of a baby's own (autologous)umbilical cord blood in the first 14 days after birth if the baby is born with signs of brain injury.


Options:
A: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
B: Arm Label: Pneumostem®; Type: N/A; Interventions: Biological: Pneumostem® | Intervention Type: BIOLOGICAL; Name: Pneumostem®; Assigned to Arm(s): Pneumostem®
C: Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®
D: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
C: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen
D: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A
B: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Arm Label: ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Biological: ranibizumab | Arm Label: aflibercept injection 2.0mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 2.0mg Q8; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Intervention Type: BIOLOGICAL; Name: ranibizumab; Assigned to Arm(s): ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q8
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: B